Traders Buy Large Volume of Call Options on PDS Biotechnology (NASDAQ:PDSB)

PDS Biotechnology Corporation (NASDAQ:PDSB) was the target of some unusual options trading on Monday. Traders acquired 4,191 call options on the company. This represents an increase of 99% compared to the typical volume of 2,103 call options.

Institutional Investors Weigh In On PDS Biotechnology

Hedge funds and other institutional investors have recently bought and sold shares of the stock. BlackRock Inc. bought a new position in shares of PDS Biotechnology in the second quarter valued at approximately $535,000. Bank of New York Mellon Corp purchased a new position in shares of PDS Biotechnology in the 2nd quarter worth about $60,000. Renaissance Technologies LLC grew its position in shares of PDS Biotechnology by 25.0% during the 1st quarter. Renaissance Technologies LLC now owns 220,800 shares of the company’s stock valued at $134,000 after acquiring an additional 44,100 shares during the period. Finally, Everhart Financial Group Inc. bought a new position in PDS Biotechnology during the third quarter valued at $29,000. 26.84% of the stock is owned by institutional investors.

PDS Biotechnology Stock Performance

NASDAQ:PDSB opened at $1.58 on Wednesday. The company has a market capitalization of $88.71 million, a PE ratio of -2.47 and a beta of 1.17. The company has a 50 day simple moving average of $0.58 and a two-hundred day simple moving average of $0.82. The company has a debt-to-equity ratio of 2.73, a quick ratio of 0.57 and a current ratio of 0.57. PDS Biotechnology has a fifty-two week low of $0.20 and a fifty-two week high of $1.79.

PDS Biotechnology (NASDAQ:PDSB) last issued its quarterly earnings results on Thursday, August 13th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.05). Research analysts anticipate that PDS Biotechnology will post -0.47 earnings per share for the current year.

Wall Street Analyst Weigh In

PDSB has been the subject of several analyst reports. Wall Street Zen raised PDS Biotechnology from a “sell” rating to a “hold” rating in a research report on Monday, October 5th. HC Wainwright reiterated a “buy” rating on shares of PDS Biotechnology in a research report on Wednesday, August 26th. Finally, Weiss Ratings upgraded PDS Biotechnology from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, September 28th. Two analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, PDS Biotechnology has an average rating of “Hold” and an average price target of $9.00.

PDS Biotechnology Company Profile

PDS Biotechnology Corporation (NASDAQ: PDSB) is a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer and infectious diseases. The company’s technology is designed to stimulate the immune system and generate antigen-specific T-cell responses against diseased cells.

PDS Biotech’s lead investigational product is PDS0101, an immunotherapy designed to target human papillomavirus type 16 (HPV16) antigens E6 and E7. The product is being evaluated in combination with other treatments for HPV16-associated cancers, including cervical, anal, and certain head and neck cancers.